Home / Treatments / Xifaxan
Xifaxan denials: what the review data shows
Independent reviewers have decided 80 published cases where an insurer denied Xifaxan — and they overturned the insurer 77.5% of the time. A denial for Xifaxan is a starting position, not a final answer.
Published decisions
80
2001–2026
Overturned
77.5%
62 denials reversed
By condition
Published outcomes when Xifaxan was denied for these conditions.
| Condition | Decisions | Overturned |
|---|---|---|
| Sibo | 24 | 70.8% |
| Ibs-d | 20 | 100% |
| Small Intestinal Bacterial Overgrowth | 14 | 85.7% |
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Xifaxanwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.